€8.65
0.25% yesterday
L&S, Jul 04, 10:54 pm CET
ISIN
JP3435750009
Symbol
2413
Index

M3 Stock price

JPY1,506.00
-148.50 8.98% 1M
-795.00 34.55% 6M
-827.00 35.45% YTD
-1,572.00 51.07% 1Y
-6,559.00 81.33% 3Y
-592.00 28.22% 5Y
+680.50 82.43% 10Y
Tokyo, Closing price Thu, Jul 04 2024
+1.50 0.10%
ISIN
JP3435750009
Symbol
2413
Index

Key metrics

Market capitalization JPY1.02t
Enterprise Value JPY888.42b
PER (TTM) P/E ratio 22.56
EV/FCF (TTM) EV/FCF 16.79
EV/Sales (TTM) EV/Sales 3.72
P/S ratio (TTM) P/S ratio 4.28
P/B ratio (TTM) P/B ratio 2.90
Dividend yield 1.26%
Last dividend (FY23) JPY19.00
Revenue growth (TTM) Revenue growth 3.49%
Revenue (TTM) Revenue JPY238.88b
EBIT (operating result TTM) EBIT JPY65.53b
Free Cash Flow (TTM) Free Cash Flow JPY52.90b
Cash position JPY179.74b
EPS (TTM) EPS JPY66.68
P/E forward 21.87
P/S forward 3.83
EV/Sales forward 3.33
Show more

Is M3 a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.

M3 Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a M3 forecast:

5x Buy
36%
7x Hold
50%
2x Sell
14%

Analyst Opinions

14 Analysts have issued a M3 forecast:

Buy
36%
Hold
50%
Sell
14%

Financial data from M3

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '24
+/-
%
59,694 59,694
4% 4%
100%
- Direct Costs 26,030 26,030
11% 11%
44%
33,664 33,664
4% 4%
56%
- Selling and Administrative Expenses 17,933 17,933
14% 14%
30%
- Research and Development Expense - -
-
-
15,731 15,731
4% 4%
26%
- Depreciation and Amortization 2,424 2,424
16% 16%
4%
EBIT (Operating Income) EBIT 13,307 13,307
26% 26%
22%
Net Profit 8,657 8,657
30% 30%
15%

In millions JPY.

Don't miss a Thing! We will send you all news about M3 directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

M3, Inc. engages in the provision of medical related services through the Internet. It operates through the following segments: Medical Portal, Evidence Solutions, Overseas, Clinical Platform, and Others. The Medical Portal segment provides the medical-related marketing support and research services. The Evidence Solutions segment includes clinical research support business, medical clinical trials management, and management support business. The Overseas segment offers marketing support and research services for medical-related firms in the United States, the United Kingdom, and South Korea. The Clinical Platform segment engages in the development, sale and support of electronic medical records. The Others segment offers information services for medical institutions and prescription drug advertising business. The company was founded on September 29, 2000 and is headquartered in Tokyo, Japan.

Head office Japan
CEO Itaru Tanimura
Employees 12,100
Founded 2000
Website corporate.m3.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today